Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2003. The report details changes in director interests regarding Ordinary Shares and American Depositary Receipts (ADRs) resulting from dividend reinvestment, share purchase plans, and retirement fund movements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director holdings rather than consolidated financial performance.
Material Changes
Material changes reported are limited to specific equity transactions:
- Dividend Reinvestment: Directors D.F. McHenry and J.H. McArthur acquired ADRs via the US Global BuyDirect Plan following the dividend paid on July 3, 2003, at a price of $40.875 per ADR.
- Share Purchase Plan: Director J.D. Coombe acquired 20 Ordinary Shares (10 personal, 10 company match) under the ShareReward Plan on July 9, 2003, at a price of £12.12 per share.
- Retirement Fund Movement: The GlaxoSmithKline US Retirement Savings Plan saw its holdings increase from 18,777,884 to 18,791,937 Ordinary Share ADRs on July 10, 2003, at an average price of $38.73.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a regulatory disclosure of insider trading activity and does not contain forward-looking statements or risk assessments.
Investor Verification Points
- Verify the impact of the reported director share acquisitions on total insider ownership percentages.
- Confirm the dividend reinvestment price of $40.875 against the market price on July 3, 2003.
- Review the terms of the ShareReward Plan to understand the matching contribution ratio utilized by Director J.D. Coombe.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or quarterly earnings release for revenue and profit metrics.